Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

158.00 +3.19 (+2.06%)
Streaming Delayed Price Updated: 5:06 AM EST, Mar 1, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Moderna Inc

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Moderna Reports 2019 Fourth Quarter and Full Year Financial Results and Highlights Advancements in Core Modalities
Moderna reports 2019 fourth quarter and full year financial results and highlights advancements in core modalities. 
From Business Wire News Releases
Moderna Ships mRNA Vaccine Against Novel Coronavirus (mRNA-1273) for Phase 1 Study
Moderna ships mRNA vaccine against novel coronavirus (mRNA-1273) to the NIH to be used in the planned Phase 1 study in the U.S. 
From Business Wire News Releases
Moderna to Present at Upcoming Investor Conferences
Moderna to present at upcoming investor conferences. 
From Business Wire News Releases
Moderna to Report Fourth Quarter and Full Year 2019 Financial Results on Wednesday, February 26th, 2020
Moderna to report fourth quarter and full year 2019 financial results on Wednesday, February 26th, 2020. 
From Business Wire News Releases
Moderna Announces Pricing of Public Offering of Shares of Common Stock
Moderna announces pricing of public offering of shares of common stock. 
From Business Wire News Releases
Moderna Announces Progress in Prophylactic Vaccines Modality with CMV Vaccine Phase 2 Study Data Now Expected in Third Quarter 2020 and Expands Investment in This Core Modality with Three New Developm
Moderna announces progress in prophylactic vaccines modality with CMV vaccine Phase 2 study data now expected in third quarter 2020. 
From Business Wire News Releases
Moderna Announces First Patient Enrolled in Phase 1/2 Study of mRNA-3704 for Methylmalonic Acidemia
Moderna announces first patient enrolled in Phase 1/2 study of mRNA-3704 for methylmalonic acidemia. 
From Business Wire News Releases
Moderna Announces Proposed Public Offering of Shares of Common Stock
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today... 
From Business Wire News Releases
Coronavirus Outbreak Sparks Renewed Interest in Combatting Infectious Diseases
FinancialBuzz.com News Commentary 
From PR Newswire
Sandra Horning, M.D. To Join Moderna’s Board of Directors
Sandra Horning, M.D. to join Moderna’s Board of Directors. 
From Business Wire News Releases
Melanie Ivarsson, Ph.D. Joins Moderna as Chief Development Officer
Melanie Ivarsson, Ph.D. joins Moderna as Chief Development Officer. 
From Business Wire News Releases
Several Drugmakers are Racing to Create and Test a Vaccine for China’s Deadly Coronavirus
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Several Drugmakers are Racing to Create and Test a Vaccine for China's Deadly Coronavirus
FN Media Group Presents USA News Group Market Commentary 
From PR Newswire
Biotech Companies Fighting Deadly Resistant Bacteria and Coronavirus
Tags healthcare/pharmaceuticals c:united/states s:washington
From EIN Presswire
Flagship Pioneering Announces Ohana Biosciences
Industry-first sperm biology platform drives understanding of how differences in sperm can impact the most important aspects of the reproductive journey 
From PR Newswire
Moderna Announces Funding Award from CEPI to Accelerate Development of Messenger RNA (mRNA) Vaccine Against Novel Coronavirus
Moderna announces funding award from CEPI to accelerate development of messenger RNA (mRNA) vaccine against novel coronavirus. 
From Business Wire News Releases
Moderna Builds on Clinical Validation of Systemic Delivery with Two Additional Development Candidates in New Autoimmune Therapeutic Area
Moderna builds on clinical validation of systemic delivery with two additional development candidates in new autoimmune therapeutic area. 
From Business Wire News Releases
Moderna Announces Additional Positive Phase 1 Data from Cytomegalovirus (CMV) Vaccine (mRNA-1647) and First Participant Dosed in Phase 2 Study
Moderna announces additional positive Phase 1 data from its cytomegalovirus (CMV) vaccine (mRNA-1647) and first participant dosed in Phase 2 study 
From Business Wire News Releases
Moderna to Provide Business and Pipeline Updates at the 2020 J.P. Morgan Healthcare Conference
Moderna to provide business and pipeline updates at the 2020 J.P. Morgan Healthcare Conference. 
From Business Wire News Releases
Flagship Unveils Newest Pioneering Platform: Ring Therapeutics
New Company Is First to Harness the Human Commensal Virome for the Development of Novel DNA and Gene Therapies 
From PR Newswire
Flagship Pioneering Strengthens Leadership With Appointment of Paul Biondi as Executive Partner
Industry veteran to enhance Flagship Pioneering executive team and help lead a new drug development initiative: Pioneering Medicines 
From PR Newswire
Moderna Announces Key 2020 Investor and Analyst Events
Moderna announced its key 2020 investor and analyst event schedule, including Manufacturing & Digital Day, Vaccines Day, Science Day and R&D Day. 
From Business Wire News Releases
François Nader, M.D., Joins Moderna’s Board of Directors
François Nader, M.D., joins Moderna’s Board of Directors. 
From Business Wire News Releases
Flagship Pioneering Unveils Cellarity, the First Company to Discover Medicines Targeting Cell Behavior
- Unites network biology, artificial intelligence, and technology to power proprietary drug discovery platform 
From PR Newswire
Flagship Pioneering Names Dr. Nancy Simonian, CEO of Syros, as Recipient of the 2019 Pioneering Leader Award
Flagship Pioneering has announced the recipient of the firm's annual Pioneering Leader Award. The 2019 award recognizes Nancy Simonian, M.D., CEO of Syros Pharmaceuticals (NASDAQ: SYRS), a company that... 
From PR Newswire
Moderna to Present at 31st Annual Piper Jaffray Healthcare Conference
Moderna to present at 31st Annual Piper Jaffray Healthcare Conference. 
From Business Wire News Releases
Torque Presents Preclinical Data for Lead Deep-Primed Cellular Immunotherapy Programs at AACR 2019 Special Conference on Tumor Immunology and Immunotherapy
Torque, a clinical-stage immuno-oncology company developing Deep Primed™ T cell immunotherapy to direct immune power deep within the tumor microenvironment, announced today additional preclinical data... 
From PR Newswire
Flagship Pioneering Appoints Prakash Raman, Ph.D. as Senior Partner and Chief Business Development Officer
Industry Leader to Enhance Pharma/BioPharma Engagement and Collaborations 
From PR Newswire
Torque Presents New Preclinical Data for Three Deep-Primed Cellular Immunotherapy Programs, Including Newly Unveiled Deep TLR, at SITC 2019 Meeting
Torque, a clinical-stage immuno-oncology company developing Deep Primed™ T cell immunotherapy to direct immune power deep within the tumor microenvironment, announced today new preclinical data for its... 
From PR Newswire
Moderna Provides Business Updates and Reports Third Quarter 2019 Financial Results
Moderna provides business updates and reports third quarter 2019 financial results. 
From Business Wire News Releases
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.